abs35.txt	background		cervical	cancer	incidence	is	significant	in	countries		such	as	southafrica		with	high	burdens	of	both	hiv	and	human	papillomavirus	(hpv)		cervicalcancer	is	largely	preventable	if	dysplasia	is	diagnosed	and	treated	early		butthere	is	debate	regarding	the	best	approaches	for	screening	and	treatment	especially	for	low-resource	settings		currently	south	africa	provides	pap	smearsfollowed	by	colposcopic	biopsy	and	leep	if	needed	in	its	public	healthfacilities		we	estimated	the	costs	and	cost-effectiveness	of	two	approaches	fortreating	cervical	intraepithelial	neoplasia	grade	2	or	higher	(cin2+)	amonghiv-infected	women		most	of	whom	were	taking	antiretroviral	treatment		at	apublic	hiv	treatment	facility	in	johannesburg		south	africa	methods		method	effectiveness	was	derived	from	an	intention-to-treat	analysis	ofdata	gathered	in	a	clinical	trial	completed	previously	at	the	study	facility		inthe	trial		women	who	were	diagnosed	with	cin2+	and	eligible	for	cryotherapy	wererandomized	to	cryotherapy	or	leep		if	women	were	cin2+	at	six	months	asdetermined	via	pap	smear	and	colposcopic	biopsy		all	women-regardless	of	theiroriginal	treatment	assignment-received	leep			cure		was	then	defined	as	theabsence	of	disease	at	12	months	based	on	pap	smear	and	colposcopic	biopsy		healthservice	costs	were	estimated	using	micro-costing	between	june	2013	and	april2014		capital	costs	were	annualized	using	a	discount	rate	of	3%		two	differentservice	volume	scenarios	were	considered		and	results	from	an	as-treated	analysiswere	considered	in	sensitivity	analysis	results		in	total		166	women	with	cin2+	were	enrolled	(86	had	leep		80	hadcryotherapy)		at	12	months		cumulative	loss	to	follow-up	was	12	8%	(11/86)	forthe	leep	group	and	13	8%	(11/80)	for	cryotherapy		based	on	the	unadjustedintention-to-treat	analysis	conducted	for	this	economic	evaluation		there	was	nosignificant	difference	in	efficacy		at	12	months		83	8%	(95%	ci	73	8-91	1)	ofwomen	with	cin2+	at	baseline	and	randomized	to	cryotherapy	were	free	of	cin2+disease		in	contrast		76	7%	(95%	ci	66	4-85	2)	of	women	assigned	to	leep	werefree	from	disease		on	average		women	initially	treated	with	cryotherapy	were	lesscostly	per	patient	randomized	at	us$	118	00	(113	91-122	10)		and	per	case		cured	at	us$	140	90	(136	01-145	79)		women	in	the	leep	group	cost	us$	162	56(157	90-167	22)	per	patient	randomized	and	us$	205	59	(199	70-211	49)	per	casecured		in	the	as-treated	analysis		which	was	based	on	trial	data		leep	was	moreefficacious	than	cryotherapy		however		the	difference	was	not	significant	cryotherapy	remained	more	cost-effective	than	leep	in	all	sensitivity	andscenario	analyses	conclusions		for	this	cost-effectiveness	analysis		using	an	intention-to-treatapproach	and	taking	into	consideration	uncertainty	in	the	clinical	and	costoutcomes		a	strategy	involving	cryotherapy	plus	leep	if	needed	at	six	months	wasdominant	to	leep	plus	leep	again	at	six	months	if	needed	for	retreatment	however		compared	to	other	studies	comparing	leep	and	cryotherapy		the	efficacyresults	were	low	in	both	treatment	groups-possibly	due	to	the	hiv-positivity	ofthe	participants		further	research	is	needed		but	at	present	choosing	the		right	treatment	option	may	be	less	important	than	ensuring	access	to	treatment	andproviding	careful	monitoring	of	treatment	outcomes	
